Navigation Links
Mode Of Action Of The Anti-Convulsant Valproate

Researchers from Australia have recently shown, using a yeast-based in vitro bioassay for steroid hormones that valproate, a commonly used anti-convulsant for the treatment of epilepsy and bipolar disorder, is an anti-androgen and anti-progestin. //

Anti-convulsant treatment is associated with a high prevalence of reproductive dysfunction compared with age-matched non-epileptics.

The researchers examined the widely used anti-convulsants valproate (VPA) and carbamazepine (CBZ) for steroidal bioactivity using a yeast-based steroid receptor-a-galactosidase reporter assay for the androgen receptor (AR), progesterone receptor (PR) or estrogen receptor (ER).

Bioassays were performed to detect agonist activity by exposing yeast to CBZ or valproate or to detect antagonist activity by exposing yeast stimulated with testosterone, progesterone or estradiol together with either valproate or CBZ for 4 (PR) or 16 (AR, ER) hours. Valproate showed dose-dependent inhibition of progesterone-induced PR- and testosterone-induced AR activity but had no ER antagonist bioactivity and no significant PR, AR or ER agonist bioactivity.

Valproate also showed a dose-dependent blockade of DHT's suppression of AR-mediated NF-êB activation in human mammalian cells.

By contrast, CBZ had no significant PR, AR or ER agonist or AR and ER antagonist bioactivity but at the highest concentration tested it did antagonize PR activity.

The authors writing in the journal Steroids (available online 13 September 2005) conclude that valproate is a non-steroidal antagonist for human AR and PR but not ER. Valproate’s androgen and progesterone antagonism at concentrations within therapeutic blood levels seems likely to contribute to the frequency of reproductive endocrine disturbances among patients treated with valproate.
'"/>




Page: 1

Related medicine news :

1. Action of nerve cells
2. Herbs With Estrogen Action Aggravate Cancer Risk
3. Immunosuppressive Action Of Fungal Metabolite - Gliotoxin
4. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
5. Action Plan Against Drug Deaths Launched
6. Ramadoss to Take Severe Action against Fertility Clinics Conducting Stem Cell Therapy
7. UN Formulates Action Plan for Relief to Recovery in Quake-hit Areas of Pakistan
8. HIV Infected Body Parts Stolen: Biomedical Tissue Services To Face Legal Action
9. India to Implement National Action Plan against TB-HIV
10. Action Urged Against Fake Medicines
11. Supreme Court Warns Medicos of Contempt Action
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: